A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Zelasudil (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms RXC007/0002
- Sponsors Redx Pharma
Most Recent Events
- 21 Aug 2024 Planned End Date changed from 1 Jun 2024 to 9 Jan 2025.
- 21 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 10 May 2024 Planned End Date changed from 1 Jun 2024 to 6 Nov 2024.